[ad_1]
This is good news for the moist AMD drug from Allergan and Molecular Partners. The duo announced Thursday that abicipar had achieved its goals in two phase III trials, proving the non-inferiority of Lucentis, the market leader.
In both 8- and 12-week diets, abicipar achieved his primary goals, but also showed David Nicholson, Allergan
"We believe that the SEQUOIA and CEDAR studies have demonstrated what we have been striving to achieve." 39, achieve, high efficacy and duration of effect that shows that the incidence of intraocular inflammation was higher than that of Lucentis. The potential to participate as a treatment for patients with AMD, "said David Nicholson, Head of Research and Development at Allergan. "We have generated significant results in these trials to address a serious unmet need.We will continue to review these data, including the results of the inflammation, and we are working to further optimize the formulation of the drug." abicipar. "
The abicipar filing is scheduled for the first half of 2019, the company said. Allergan will request a meeting with the FDA to discuss his BLA submission. Full details of the data on the primary and secondary parameters will be presented at a future scientific conference.
[ad_2]Tags Allergan AMD Drug Endpoints Lucentis Molecular News noninferiority Partners PhIII shows wet wins
